Showing results (1121-1130 of 5,723) with videos related to

Sort By:
Pageof 573
Medical Oncology (Northwood, London, England)|June 30, 2014
Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancerXiao Wu, Yi-xuan Zhuang, Chao-qun Hong, et al.
Medical Oncology (Northwood, London, England)|June 14, 2014
Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOPGuoqi Song, William C Cho, Ling Gu, et al.
Medical Oncology (Northwood, London, England)|June 15, 2014
Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemiaShu-mei Wang, Lu-lu Sun, Wei-xin Zeng, et al.
Medical Oncology (Northwood, London, England)|June 16, 2014
High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferationGuizhi Dong, Xiaoling Liang, Deguang Wang, et al.
Medical Oncology (Northwood, London, England)|June 16, 2014
URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasionWei Peng, Jun Zhang, Jie Liu
Medical Oncology (Northwood, London, England)|June 19, 2014
CYP1A1 Ile462Val polymorphism and colorectal cancer risk in Polish patientsJustyna Gil, Paweł Gaj, Błażej Misiak, et al.
Medical Oncology (Northwood, London, England)|June 20, 2014
Overexpression of NUAK1 is associated with disease-free survival and overall survival in patients with gastric cancerXiao-tian Ye, Ai-jun Guo, Peng-fei Yin, et al.
Medical Oncology (Northwood, London, England)|January 25, 2015
Erratum to: Negative feedback of miR-29 family TET1 involves in hepatocellular cancerLi Li Lin, Wei Wang, ZhaoYang Hu, et al.
Medical Oncology (Northwood, London, England)|July 3, 2014
GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han populationChaoyin Jiang, Hua Chen, Lei Shao, et al.
Medical Oncology (Northwood, London, England)|July 3, 2014
How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observationBin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, et al.
Pageof 573